Takeda rebuffed (again) in long quest for FDA drug OK

Four months before Japan's Takeda will get hit with a tsunami of generic competition for the diabetes blockbuster Actos, the FDA has once again rebuffed the company's application to sell the experimental drug alogliptin. More than 5 years since it originally sought an approval, the drug giant says that the agency wants more data before it can issue an approval for the treatment, which was intended to replace Actos.

The move to re-file the drug was always considered something of a gamble. Takeda and its partner Furiex ($FURX) launched new studies after the treatment was turned down in 2009. Those trials won't be complete until 2014, though the companies had hoped that interim cardio data would suffice for an approval.

Takeda says those ongoing studies, along with data gathered in markets outside the U.S., should satisfy the regulators. "We will immediately request a meeting with the FDA to determine the appropriate next steps and are committed to addressing outstanding issues," said Takeda regulatory chief Thomas Harris in a statement. "We remain confident in the benefit that alogliptin will bring to patients with type 2 diabetes in the U.S., if approved."

The FDA has never been easy on diabetes drugs, and in recent years regulators have toughened up even more with demands for extensive safety data. Shares of Furiex plunged more than 20% on this latest setback.  

- get the press release
- here's the story from Bloomberg

Suggested Articles

While Sanofi is looking to move more of its R&D in-house, there is still room for deals, and today it’s penned a big one with Fierce 15 winner Kymera

Tranquis Therapeutics launched with $30 million to create a new class of medicines for illnesses like amyotrophic lateral sclerosis and Alzheimer’s.

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.